Navigation Links
Switching to new anti-bacterial targets: Riboswitches

The recently emerged field of bacterial riboswitches may be a good hunting ground for effective targets against bacterial infection, according to a report by Yale researchers in the journal Chemistry and Biology.

Riboswitches are RNA elements that control gene expression in essential metabolic pathways. Researchers in the laboratory of Ronald R. Breaker, the Henry Ford II Professor of Molecular, Cellular and Developmental Biology at Yale, showed that a riboswitch controlling vitamin B1 (thiamine) levels is disrupted in the presence of pyrithiamine, a toxic compound related to the vitamin.

Bacteria and fungi fail to grow in pyrithiamine and become resistant by acquiring mutations in their riboswitches. This work, in combination with the recently solved crystal structures of purine riboswitches, opens a path to the directed design of drugs targeting riboswitches for use as antibiotics.

According to the researchers, it is inevitable that bacteria will evolve and that the drugs we use to cure bacterial infections will eventually become ineffective. While it is often possible to alter existing drugs slightly, they suggest that a longer term and more attractive solution is to create entirely new drugs that target bacteria in completely new ways. This approach lengthens the useful clinical lifetime of a drug and makes it possible to tackle resistant 'superbugs' with combinations of drugs.

The analog, pyrithiamine, was synthesized decades ago to study the then new field of vitamin nutrition. It was quickly found to be toxic but the mechanism was incompletely understood. Breaker and coworkers show that pyrithiamine is metabolized and binds to the riboswitch controlling thiamine.

Co-authors at Yale on the work are Narasimhan Sudarsan, Smadar Cohen-Chalamish, Shingo Nakamura and Gail Mitchel l Emilsson. The study was funded by the Defense Advanced Research Projects Agency, National Institutes of Health, and the David and Lucile Packard Foundation.

Breaker, a Howard Hughes Medical Institute Investigator, is co founder of BioRelix, a company pursuing licensing of intellectual property related to riboswitches.


'"/>

Source:Yale University


Related biology news :

1. Switching genes to overdrive improves muscular dystrophy symptoms in mice
2. Mayo Clinic collaboration mining of ancient herbal text leads to potential new anti-bacterial drug
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/14/2017)... PARIS , June 15, 2017  IBM (NYSE: IBM ... the international tech event dedicated to developing collaboration between startups ... on June 15-17. During the event, nine startups will ... deliver value in various industries. ... in the international market, with a 30 percent increase in ...
(Date:4/24/2017)... , April 24, 2017 Janice ... partner with  Identity Strategy Partners, LLP (IdSP) , ... or without President Trump,s March 6, 2017 ... Entry , refugee vetting can be instilled with greater ... (Right now, all refugee applications are suspended by ...
(Date:4/13/2017)... India , April 13, 2017 According to ... Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication Type, ... MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 Billion ... Growth Rate (CAGR) of 17.3%. ... MarketsandMarkets ...
Breaking Biology News(10 mins):
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... The ... use of health IT to create efficiencies in healthcare information exchange and a statutory ... W. Rucker, MD, head of the federal Office of the National Coordinator for Health ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ken Hanson, a medical imaging research scientist ... have been selected as this year’s recipients of two top awards from SPIE, ... along with other honorees to accept their awards at a banquet in San Diego, ...
(Date:6/22/2017)... ... June 21, 2017 , ... RMC Pharmaceutical Solutions, Inc. announces ... Reinhardt to manage the new site. , Tim has 25 years of pharmaceutical ... recent role as the Director of Manufacturing and Supplier Quality Assessment. This ...
(Date:6/22/2017)... ... 2017 , ... For the months of May and June, ... series on “Cell Therapy Regulation” for its regenerative medicine followship. The ... regulatory challenges of stem cell medical research. , Stem cell clinical trials present ...
Breaking Biology Technology: